Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience.

Jeffrey, Angus W; Abu-Rgeef, Reeham; Picardo, Sherman; Menon, Shankar; So, Kenji; Venugopal, Kannan

Jeffrey, Angus W; Abu-Rgeef, Reeham; Picardo, Sherman; Menon, Shankar; So, Kenji; Venugopal, Kannan.

Afiliación

Jeffrey AW; Department of Gastroenterology, Royal Perth Hospital, Perth, Australia (Angus Jeffrey, Reeham Abu-Rgeef, Sherman Picardo, Shankar Menon, Kenji So, Kannan Venugopal).
Abu-Rgeef R; Department of Gastroenterology, Royal Perth Hospital, Perth, Australia (Angus Jeffrey, Reeham Abu-Rgeef, Sherman Picardo, Shankar Menon, Kenji So, Kannan Venugopal).
Picardo S; Department of Gastroenterology, Royal Perth Hospital, Perth, Australia (Angus Jeffrey, Reeham Abu-Rgeef, Sherman Picardo, Shankar Menon, Kenji So, Kannan Venugopal).
Menon S; Department of Gastroenterology, Royal Perth Hospital, Perth, Australia (Angus Jeffrey, Reeham Abu-Rgeef, Sherman Picardo, Shankar Menon, Kenji So, Kannan Venugopal).
So K; Department of Gastroenterology, Royal Perth Hospital, Perth, Australia (Angus Jeffrey, Reeham Abu-Rgeef, Sherman Picardo, Shankar Menon, Kenji So, Kannan Venugopal).
Venugopal K; Department of Gastroenterology, Royal Perth Hospital, Perth, Australia (Angus Jeffrey, Reeham Abu-Rgeef, Sherman Picardo, Shankar Menon, Kenji So, Kannan Venugopal).

Ann Gastroenterol ; 36(5): 549-554, 2023.

Article en En | MEDLINE | ID: mdl-37664232